Pramipexole Reduces the Prevalence of Fatigue in Patients with Parkinson's Disease

• Morita Akihiko

  Division of Neurology, Department of Medicine, Nihon University School of Medicine, Japan

• Okuma Yasuyuki

  Department of Neurology, Juntendo University Shizuoka Hospital, Japan

• Kamei Satoshi

  Division of Neurology, Department of Medicine, Nihon University School of Medicine, Japan

• Yoshii Fumihito

  Department of Neurology, Tokai University School of Medicine, Japan

• Yamamoto Toshimasa

  Department of Neurology, Faculty of Medicine, Saitama Medical University, Japan

• Hashimoto Shiori

  Department of Neurology, Tokyo Women's Medical University, Japan

• Utsumi Hiroya

  The Third Department of Internal Medicine, Division of Neurology, Tokyo Medical University, School of Medicine, Japan

• Hatano Taku

  Department of Neurology, Juntendo University School of Medicine, Japan

• Hattori Nobutaka

  Department of Neurology, Juntendo University School of Medicine, Japan

• Matsumura Miyuki

  Institute of Geriatrics, Tokyo Women's Medical University, Japan

• Takahashi Kazushi

  Department of Neurology, Keio University School of Medicine, Japan

• Nogawa Shigeru

  Department of Medicine, Tokyo Dental College Ichikawa General Hospital, Japan

• Watanabe Yuka

  Department of Neurology, Dokkyo Medical University, Japan

• Miyamoto Tomoyuki

  Department of Neurology, Dokkyo Medical University, Japan

• Miyamoto Masayuki

  Department of Neurology, Dokkyo Medical University, Japan

• Hirata Koichi

  Department of Neurology, Dokkyo Medical University, Japan

抄録

Objective The aim of this multicenter cross-sectional study was to assess the relation between fatigue in a large number of Japanese patients with Parkinson's disease (PD) and drugs taken to treat PD.<br> Method We used the 16-item Parkinson Fatigue Scale (PFS-16), which was designed to assess fatigue exclusively associated with PD. Multiple logistic regression analyses were used to assess the relation between antiparkinson drugs and fatigue in PD.<br> Results A total of 350 non-demented PD patients were enrolled. Fatigue (PFS score of ≥4) was revealed in 319 patients (91%). Pramipexole was administered to 24% of PD patients. Multiple logistic regression analysis revealed that the administration of Pramipexole was significantly related to low rates of fatigue in PD patients with Hoehn and Yahr stage <3 (p=0.011, odds ratio=5.23, 95% confidence interval; 1.47-18.63).<br> Conclusion The reduced fatigue in PD patients was observed in taking Pramipexole.<br>

収録刊行物

• Internal Medicine

  Internal Medicine 50 (19), 2163-2168, 2011

  一般社団法人 日本内科学会

キーワード

• Parkinson's disease
• fatigue
• Pramipexole

詳細情報

• CRID: 1390282679846798592
• NII論文ID: 130001087898
• DOI: 10.2169/internalmedicine.50.5456
• ISSN: 13497235
• ISSN: 09182918
• Web Site: http://www.jstage.jst.go.jp/article/internalmedicine/50/19/50_19_2163/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2012227946
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可